Dieser Anti-Trop2 (Sacituzumab Biosimilar) Antikörper ist ein Humanized Monoklonal Antikörper zur Detektion von Trop2 (Sacituzumab Biosimilar) in FACS und in vivo. Geeignet für Human.
Produktnummer ABIN7795132
Kurzübersicht für Rekombinanter Trop2 (Sacituzumab Biosimilar) Antikörper (ABIN7795132)
Target
Trop2 (Sacituzumab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser Trop2 (Sacituzumab Biosimilar) Antikörper ist unkonjugiert
What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.